Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PFE 
Pfizer Inc (PFE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: PFE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $29.04
1 Year Target Price $29.04
| 7 | Strong Buy |
| 2 | Buy |
| 15 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.88% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 146.12B USD | Price to earnings Ratio 14.94 | 1Y Target Price 29.04 |
Price to earnings Ratio 14.94 | 1Y Target Price 29.04 | ||
Volume (30-day avg) 25 | Beta 0.42 | 52 Weeks Range 19.83 - 27.21 | Updated Date 12/5/2025 |
52 Weeks Range 19.83 - 27.21 | Updated Date 12/5/2025 | ||
Dividends yield (FY) 6.65% | Basic EPS (TTM) 1.72 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.65% | Operating Margin (TTM) 35.28% |
Management Effectiveness
Return on Assets (TTM) 5.19% | Return on Equity (TTM) 10.6% |
Valuation
Trailing PE 14.94 | Forward PE 8.44 | Enterprise Value 191247542104 | Price to Sales(TTM) 2.33 |
Enterprise Value 191247542104 | Price to Sales(TTM) 2.33 | ||
Enterprise Value to Revenue 3.05 | Enterprise Value to EBITDA 10.31 | Shares Outstanding 5685707552 | Shares Floating 5675928135 |
Shares Outstanding 5685707552 | Shares Floating 5675928135 | ||
Percent Insiders 0.08 | Percent Institutions 67.41 |
Upturn AI SWOT
Pfizer Inc
Company Overview
History and Background
Founded in 1849 by Charles Pfizer and Charles Erhart, Pfizer started as a fine-chemicals company in Brooklyn, NY. Significant milestones include the development of penicillin during World War II and the subsequent expansion into pharmaceuticals. Over time, Pfizer has grown through organic growth and acquisitions to become one of the world's largest pharmaceutical companies.
Core Business Areas
- Biopharma: Focuses on developing and marketing innovative medicines and vaccines across various therapeutic areas, including oncology, inflammation & immunology, internal medicine, vaccines, and rare diseases.
Leadership and Structure
Pfizer is led by CEO Albert Bourla. The organizational structure is divided into business units focused on different therapeutic areas and functional divisions supporting research, development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Comirnaty (COVID-19 Vaccine): An mRNA-based vaccine developed in partnership with BioNTech. Revenue for 2023 was $11.2 billion. Competitors include Moderna (MRNA) and Novavax (NVAX).
- Paxlovid (COVID-19 Treatment): An oral antiviral used to treat COVID-19. Revenue for 2023 was $1.3 billion. Competitors include Gilead Sciences (GILD) (Veklury).
- Prevnar Family: Pneumococcal conjugate vaccines used to prevent pneumococcal disease. Revenue for Prevnar 13 and Prevnar 20 totaled $6.4 billion in 2023. Competitors include Merck (MRK) (Pneumovax 23).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, strict regulatory requirements, and intense competition. Key trends include the development of personalized medicine, the rise of biosimilars, and increasing pressure on drug pricing.
Positioning
Pfizer is a leading player in the pharmaceutical industry, with a strong portfolio of innovative medicines and vaccines. Its competitive advantages include its scale, global reach, R&D capabilities, and strong brand recognition.
Total Addressable Market (TAM)
The global pharmaceutical market is expected to reach over $1.7 trillion by 2027. Pfizer is well-positioned to capture a significant portion of this TAM through its diverse product portfolio and R&D pipeline.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Global presence and distribution network
- Diverse product portfolio
- Strong financial position
- Experienced management team
Weaknesses
- Reliance on patent protection
- Exposure to generic competition
- Dependence on successful drug development
- Public perception and reputation
- Recent revenue decline due to reduced COVID product demand
Opportunities
- Growth in emerging markets
- Development of new innovative therapies
- Strategic acquisitions and partnerships
- Expansion into personalized medicine
- Increasing demand for preventative care
Threats
- Increasing regulatory scrutiny
- Pricing pressures and reimbursement challenges
- Generic competition and biosimilars
- Product liability litigation
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- ABBV
- NVS
- LLY
Competitive Landscape
Pfizer faces intense competition from other major pharmaceutical companies. Its advantages include its scale, global reach, and strong brand recognition. However, it also faces challenges related to generic competition and pricing pressures.
Major Acquisitions
Seagen
- Year: 2023
- Acquisition Price (USD millions): 43000
- Strategic Rationale: Strengthens Pfizer's oncology pipeline and expands its presence in the antibody-drug conjugate (ADC) market.
Growth Trajectory and Initiatives
Historical Growth: Pfizer experienced significant growth during the COVID-19 pandemic due to its vaccine and treatment products. However, growth has slowed down recently due to decreased demand for these products.
Future Projections: Analysts project moderate revenue growth in the coming years, driven by new product launches and continued demand for existing products in key therapeutic areas.
Recent Initiatives: Recent initiatives include strategic acquisitions to expand its pipeline, cost-cutting measures to improve profitability, and investments in R&D to develop new innovative therapies.
Summary
Pfizer is a large pharmaceutical company with a diversified product portfolio and a strong global presence. Recent financial performance has been impacted by declining COVID-19 product demand. The Seagen acquisition should bolster Pfizer's oncology business. Pfizer will need to carefully manage pricing pressures and competition.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Pfizer Investor Relations
- SEC Filings (10-K, 10-Q)
- Yahoo Finance
- Company Websites
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pfizer Inc
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 1942-06-22 | Chairman of the Board & CEO Dr. Albert Bourla D.V.M., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 81000 | Website https://www.pfizer.com |
Full time employees 81000 | Website https://www.pfizer.com | ||
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.